Stage IB-IIIA NSCLC
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (NCT07492342) | Jianxing He | 2026-01-29 |
Track Stage IB-IIIA NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.